ECSS
ROIV icon

Eurizon Capital SGR SpA’s Roivant Sciences ROIV Stock Holding History

Eurizon Capital SGR SpA’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2K Sell
467
-10,573
-96% -$312K ﹤0.01% 1153
2026
Q1 		$305K Buy
+11,040
New +$284K ﹤0.01% 695

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Eurizon Capital SGR SpA's ROIV Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its Roivant Sciences (ROIV) stake by 96% in Q2 2026, selling an estimated $312K and leaving 467 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.

Eurizon Capital SGR SpA first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. The position peaked at $305K in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Eurizon Capital SGR SpA held 467 shares of Roivant Sciences worth $16.2K as of Q2 2026.
  • Eurizon Capital SGR SpA sold 10,573 Roivant Sciences shares in Q2 2026, an estimated $312K.
  • Roivant Sciences made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #1153 holding.
  • Eurizon Capital SGR SpA first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
  • Eurizon Capital SGR SpA's Roivant Sciences position peaked at $305K in Q1 2026.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.